Here's Why Axovant Sciences Dropped Today [The Motley Fool]
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: The Motley Fool
The company's future is in serious doubt. Maxx Chatsko ( TMFBlacknGold ) Jan 8, 2018 at 12:21PM What happened Shares of clinical-stage biopharma Axovant Sciences ( NASDAQ:AXON ) fell by nearly 50% today after the company announced that its leading drug candidate, intepirdine, failed to meet its primary efficacy endpoint in any of three phase 2 trials evaluating the compound as a potential treatment for a specific type of dementia. As a result of the overwhelming clinical evidence accumulated to date, the company will no longer seek to develop the drug. Axovant Sciences announced a separate batch of phase 2 data from another drug candidate, nelotanserin, as a potential treatment for similar types of dementia. The drug candidate met its primary endpoint, but it was safety, not efficacy. Regarding improvement in symptoms, the biopharma noted that
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $400.00 price target on the stock.MarketBeat
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safety [Yahoo! Finance]Yahoo! Finance
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safetyPR Newswire
- Axon Enterprise (AXON) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 4/19/24 - Form POSASR
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEFA14A
- AXON's page on the SEC website